Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023 -November 03, 2023 at 12:01 pm EDT

Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of...

Related Keywords

Boston ,Massachusetts ,United States ,California ,San Diego ,Dan Passeri ,Matteo Levisetti ,Jennifer Eva Selfridge ,Maya Romanchuk ,Christine Chung ,Marie Campinell ,Lifesci Communications ,Society For Immunotherapy Of Cancer ,Nasdaq ,Moffitt Cancer Center ,Cue Biopharma Inc ,University Hospitals Cleveland Medical Center ,Corporate Communications ,Department Of Head ,H Lee Moffitt Cancer Center ,Securities Exchange ,Twitter ,Drug Administration ,Wilm Tumor ,Anniversary Annual Meeting ,Neck Endocrine Oncology ,Cue Biopharma ,Fast Track ,Exhibit Halls ,Scientific Publications ,Pembrolizumab With ,Metastatic Head ,Neck Squamous Cell Carcinoma ,Updated Results ,Pembrolizumab Alone ,Subgroup Analysis ,Programmed Death ,Selective Targeting ,Securities Act ,Securities Exchange Act ,Risk Factors ,Financial Condition ,Annual Report ,Quarterly Report ,Markets ,